undamentalytics Newsletter
Sign in

Kewaunee Scientific Corp (KEQU) stock

Add to watchlist

Add holding +

NASDAQ: KEQU Nasdaq Industrial Machinery & Supplies & Components Next results ~December 9, 2026

D Fundamentals grade

Kewaunee Scientific Corp is a US-listed company in the industrial machinery & supplies & components industry. Its financial year ends in April.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($102.34) is 3.06x the share price ($33.42) and 2.50x the median of our other models ($40.91); the other models don't support a gap this wide.

Price vs value

Under review: our cash-flow value ($102.34) is 3.06x the share price ($33.42) and 2.50x the median of our other models ($40.91); the other models don't support a gap this wide. We'll show the comparison once resolved.

Kewaunee Scientific Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds11 adding, 8 cuttingOf 3 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Kewaunee Scientific files

Where Kewaunee Scientific stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $277m, up 5.3% on a year earlier, slower than the 17.3% growth a quarter earlier. Free-cash-flow margin fell to 3.9% from 7.1% a year earlier. Operating margin narrowed to 5.4% from 7.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 4 of our 6 financial-health checks.

Our model value for Kewaunee Scientific is under review, so past values are not shown until it is resolved.

Source: 10-Q filed September 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 9, 2026 (estimated)

Kewaunee Scientific Corp's trailing-twelve-month revenue grew 5.3% year on year, with a free-cash-flow margin of 3.9%. Where it stands out: long-term debt as % of assets of 7.9% ranks 9 of 59 industrial machinery & supplies & components companies we cover. Where it lags: change in growth rate of -11.9pp ranks 69 of 75 industrial machinery & supplies & components companies we cover.

Our discounted-cash-flow model values the business at ~$100 per share in the base case (~$76–$140 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 128% in the quarter to 2019-04-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Kewaunee Scientific Corp's latest figures clears our strength thresholds.

Things to watch

  • Growth slowing. The growth rate is 11.9 points lower than a quarter earlier.
  • Below peers: days sales outstanding. Days sales outstanding of 77 days ranks 50 of 65 industrial machinery & supplies & components companies we cover (median 63 days).

Latest results: FY2027 Q1

Filed September 11, 2026
Earnings per share
-$0.15 against an average estimate of $0.53: missed by 128.3%
Revenue
$66m, down 6.7% on a year earlier
Share reaction
-4.1% in the first session after the results on September 9, 2026, against -1.1% for the S&P 500

Kewaunee Scientific's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.1%
  • 1 week+3.0%
  • 1 month-2.2%
  • This year-10.7%
  • 1 year-20.1%
  • 5 years+158.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$277M
Operating margin
5.4%
Net margin
3.0%
EPS (TTM, diluted)
$2.77

Growth

Revenue growth
+5.3%
Change in growth rate
−11.9 pts
Share count change
−0.2%

Cash

Free cash flow (TTM)
$10.9M
FCF margin
3.9%
Stock pay % of revenue
1.3%

Earnings

Last results
September 9, 2026
Next results (est.)
December 9, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Deal
  2. Results
  3. Shareholder vote
  4. Announcement
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kewaunee Scientific Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($102.34) is 3.06x the share price ($33.42) and 2.50x the median of our other models ($40.91); the other models don't support a gap this wide.

Our value per share comes from a discounted-cash-flow model of Kewaunee Scientific Corp's free cash flow after stock-based pay ( $14.2M, FY2027 Q1 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Kewaunee Scientific Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.94 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$100 ~$76–$140 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$41 ~$54–$88 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$39 ~$29–$54 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$43 ~$37–$51 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kewaunee Scientific Corp with Industrial Machinery & Supplies & Components in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$15.15$21.30$33.33$22.15$10.23$12.00$14.26$16.25$35.70$31.67$37.01$33.40
Market value$41m$58m$93m$62m$28m$33m$40m$47m$105m$94m$110m$99m
+ Net debt (− = net cash)−$2m−$10m−$7m−$9m$354000−$5m−$3m−$4m−$20m$24m$10m$11m
Enterprise value$39m$48m$85m$53m$28m$28m$37m$43m$85m$118m$121m$110m
Multiples
Price / sales 0.3x0.4x0.6x0.4x0.2x0.2x0.2x0.2x0.5x0.4x0.4x0.4x
Price / earnings 10.7x12.9x17.5x40.5x———63.9x5.6x8.3x11.5x12.1x
Price / free cash flow 8.0x6.4x——16.6x———6.9x7.5x7.5x9.1x
EV / EBITDA 4.7x5.2x6.7x11.2x92.2x20.4xn/m5.2x4.0x5.2x5.2x5.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

29 /100

Weak moat

How hard Kewaunee Scientific's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 4 / 20

    Net income has been a median 3.9% of total assets over 10 years.

  • Pricing power 5 / 20

    Gross margin has been a median 19.1%, moving by 5.3 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 4.5%; its worst year was -2.3%.

  • Cash conversion 6 / 20

    Free cash flow was positive in 6 of 10 years, at a median 0.2% of revenue.

  • Discipline 14 / 20

    The diluted share count rose 7.5% over five years; stock-based pay has been a median 0.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Kewaunee Scientific Corp: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Apr 2019 $0.53 −$0.15 −128.3%
Jan 2019 $0.56 −$0.01 −101.8%
Oct 2018 $0.61 $0.51 −16.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, September 9, 2026

No numeric guidance in Kewaunee Scientific Corp's latest earnings release (filed September 9, 2026). Some companies give their outlook only on the earnings call.

Positioning

Short interest
1.5%
of tradable shares
Days to cover
8.13
at average volume
Short interest, 1 month
−19%
to October 15, 2026
Held by institutions
42%
of shares
Held by insiders
24.4%
of shares
Employees
1,231
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −20.1%

$41.82 on October 31, 2025 to $33.40

ThenNowEffect
Revenue (last 12 months) $263m $277m +5.3%
Net margin 4.7% 3.0% −36.5%
P/E multiple 10.1x 12.1x +19.2%
Share count 3m 3m +0.2%

Biggest factor: net margin.

Last 3 years +83.0%

$18.25 on November 3, 2023 to $33.40

ThenNowEffect
Revenue (last 12 months) $219m $277m +26.5%
Net margin 1.8% 3.0% +64.4%
P/E multiple 13.5x 12.1x −10.4%
Share count 3m 3m −1.7%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KEQU+2%+26%+82%+113%−40%−11%
Industry peers (median)+19%−15%+19%+2%+13%+5%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KEQU25%42%67%67%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KEQU−18%−22%−15%−44%−55%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 80% from June 26, 2018 to April 2, 2020. Getting back needed a 399% gain, reached on April 4, 2024, 1463 days after the low.

Price behaviour

52-week range
$32.10 – $43.10
From 52-week high
−22.5%
vs 50-day average
−3.3%
vs 200-day average
−9.2%
Volatility (1 year)
35%
Beta vs S&P 500
0.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±14.8%
After a week
6 up, 6 down
typical move ±15.8%
After a month
5 up, 7 down
typical move ±25.7%
Results releasedNext dayS&P 500 next day5 days21 days
September 9, 2026 −4.1% −1.1% −1.3% −6.1%
June 23, 2026 −8.3% −1.5% −4.2% −1.9%
March 11, 2026 −15.3% −1.6% −18.5% −16.9%
December 10, 2025 −1.3% +0.9% +0.3% −3.3%
September 10, 2025 −19.7% +1.1% −15.7% −19.6%
June 26, 2025 +40.0% +1.3% +45.4% +41.7%
March 12, 2025 +2.2% −0.8% +4.5% −26.8%
December 11, 2024 +31.0% +0.3% +28.7% +35.6%
September 11, 2024 −2.5% +1.9% −9.2% −23.5%
June 26, 2024 +19.7% +0.3% +30.5% +49.7%
March 6, 2024 −1.0% +1.5% −0.1% +20.1%
December 6, 2023 +33.1% +0.4% +31.8% +63.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Kewaunee Scientific Corp in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Kewaunee Scientific Corp
$150M $200M $250M $300M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $215.1M Revenue (TTM), FY24 Q3: $201M Revenue (TTM), FY24 Q4: $203.8M Revenue (TTM), FY25 Q1: $202.3M Revenue (TTM), FY25 Q2: $199.6M Revenue (TTM), FY25 Q3: $220M Revenue (TTM), FY25 Q4: $240.5M Revenue (TTM), FY26 Q1: $263.2M Revenue (TTM), FY26 Q2: $285.5M Revenue (TTM), FY26 Q3: $287.7M Revenue (TTM), FY26 Q4: $282M Revenue (TTM), FY27 Q1: $277.2M $277.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $215.1M
FY24 Q3 $201M
FY24 Q4 $203.8M
FY25 Q1 $202.3M
FY25 Q2 $199.6M
FY25 Q3 $220M
FY25 Q4 $240.5M
FY26 Q1 $263.2M
FY26 Q2 $285.5M
FY26 Q3 $287.7M
FY26 Q4 $282M
FY27 Q1 $277.2M
Revenue growth, TTM YoY Kewaunee Scientific Corp
-20% 0% 20% 40% 60% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: 10.3% Revenue growth, TTM YoY, FY24 Q3: -6.6% Revenue growth, TTM YoY, FY24 Q4: -7.2% Revenue growth, TTM YoY, FY25 Q1: -7.7% Revenue growth, TTM YoY, FY25 Q2: -7.2% Revenue growth, TTM YoY, FY25 Q3: 9.4% Revenue growth, TTM YoY, FY25 Q4: 18.0% Revenue growth, TTM YoY, FY26 Q1: 30.1% Revenue growth, TTM YoY, FY26 Q2: 43.0% Revenue growth, TTM YoY, FY26 Q3: 30.8% Revenue growth, TTM YoY, FY26 Q4: 17.3% Revenue growth, TTM YoY, FY27 Q1: 5.3% 5.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 10.3%
FY24 Q3 -6.6%
FY24 Q4 -7.2%
FY25 Q1 -7.7%
FY25 Q2 -7.2%
FY25 Q3 9.4%
FY25 Q4 18.0%
FY26 Q1 30.1%
FY26 Q2 43.0%
FY26 Q3 30.8%
FY26 Q4 17.3%
FY27 Q1 5.3%
Operating margin (TTM) Kewaunee Scientific Corp
5% 6% 7% 8% 9% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: 6.5% Operating margin (TTM), FY24 Q3: 7.7% Operating margin (TTM), FY24 Q4: 9.0% Operating margin (TTM), FY25 Q1: 8.4% Operating margin (TTM), FY25 Q2: 8.2% Operating margin (TTM), FY25 Q3: 6.7% Operating margin (TTM), FY25 Q4: 7.4% Operating margin (TTM), FY26 Q1: 7.6% Operating margin (TTM), FY26 Q2: 6.9% Operating margin (TTM), FY26 Q3: 7.0% Operating margin (TTM), FY26 Q4: 5.9% Operating margin (TTM), FY27 Q1: 5.4% 5.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 6.5%
FY24 Q3 7.7%
FY24 Q4 9.0%
FY25 Q1 8.4%
FY25 Q2 8.2%
FY25 Q3 6.7%
FY25 Q4 7.4%
FY26 Q1 7.6%
FY26 Q2 6.9%
FY26 Q3 7.0%
FY26 Q4 5.9%
FY27 Q1 5.4%
FCF margin (TTM) Kewaunee Scientific Corp
-5% 0% 5% 10% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: -0.2% FCF margin (TTM), FY24 Q3: 6.1% FCF margin (TTM), FY24 Q4: 7.5% FCF margin (TTM), FY25 Q1: 3.8% FCF margin (TTM), FY25 Q2: 8.0% FCF margin (TTM), FY25 Q3: 1.8% FCF margin (TTM), FY25 Q4: 5.2% FCF margin (TTM), FY26 Q1: 7.1% FCF margin (TTM), FY26 Q2: 1.8% FCF margin (TTM), FY26 Q3: 6.6% FCF margin (TTM), FY26 Q4: 5.2% FCF margin (TTM), FY27 Q1: 3.9% 3.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -0.2%
FY24 Q3 6.1%
FY24 Q4 7.5%
FY25 Q1 3.8%
FY25 Q2 8.0%
FY25 Q3 1.8%
FY25 Q4 5.2%
FY26 Q1 7.1%
FY26 Q2 1.8%
FY26 Q3 6.6%
FY26 Q4 5.2%
FY27 Q1 3.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Kewaunee Scientific took in during FY2026, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $282M
  2. Cost of revenue $202M · 71.5%
  3. Gross profit $80.4M · 28.5%
  4. Other operating costs $62.8M · 22.3%
  5. Operating income $16.7M · 5.9%
  6. Income tax $3.3M · 1.2%
  7. Interest and other $3.8M · 1.4%
  8. Net income $9.6M · 3.4%

Shares of revenue. Source: Kewaunee Scientific's 10-K for FY2026, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Apr 2010 2011 Apr 2011 2012 Apr 2012 2013 Apr 2013 2014 Apr 2014 2015 Apr 2015 2016 Apr 2016 2017 Apr 2017 2018 Apr 2018 2019 Apr 2019 2020 Apr 2020 2021 Apr 2021 2022 Apr 2022 2023 Apr 2023 2024 Apr 2024 2025 Apr 2025 2026 Apr 2026 LTM Jul 2026
Income
Revenue 99 100 103 117 111 119 129 139 158 147 148 147 169 219 204 240 282 277
Gross profit 21 19 19 22 22 22 24 27 32 25 23 24 24 36 52 69 80 79
EBITDA 8 6 5 8 9 8 8 9 13 5 0 1 0 8 21 23 23 21
Operating income 6 3 3 5 6 5 6 7 10 2 −2 −1 −3 5 18 18 17 15
Net income 4 2 1 3 4 4 4 5 5 2 −5 −4 −6 1 19 11 10 8
Diluted EPS $1.39 $0.72 $0.40 $1.17 $1.48 $1.33 $1.42 $1.66 $1.90 $0.55 −$1.70 −$1.33 −$2.20 $0.25 $6.38 $3.83 $3.22 $2.77
Growth (year on year)
Revenue — +0.9% +2.8% +13.9% −5.1% +6.9% +8.2% +7.7% +14.1% −7.3% +0.7% −0.0% +14.5% +30.0% −7.2% +18.0% +17.3% +5.3%
EBITDA — −31.0% −4.7% +47.5% +7.4% −7.9% +5.7% +11.5% +37.2% −63.1% −93.4% — — — +160.1% +5.2% +2.1% −16.1%
Operating income — −45.8% −14.1% +94.5% +13.0% −12.4% +9.0% +14.8% +51.6% −78.7% — — — — +240.8% −2.9% −5.9% −24.7%
Net income — −48.2% — — +28.0% −9.4% +7.7% +18.8% +17.0% −71.0% — — — — — −39.2% −15.7% −33.1%
Diluted EPS — −48.2% — — +26.5% −10.1% +6.8% +16.9% +14.5% −71.1% — — — — — −40.0% −15.9% −33.0%
Margins
Gross margin 21.6% 19.3% 18.6% 19.0% 19.8% 18.3% 18.4% 19.2% 20.3% 17.3% 15.9% 16.3% 14.3% 16.2% 25.5% 28.6% 28.5% 28.6%
EBITDA margin 8.2% 5.6% 5.2% 6.8% 7.7% 6.6% 6.4% 6.7% 8.0% 3.2% 0.2% 0.9% 0.1% 3.8% 10.5% 9.4% 8.2% 7.7%
Operating margin 5.9% 3.2% 2.6% 4.5% 5.4% 4.4% 4.4% 4.7% 6.3% 1.4% −1.6% −0.9% −1.5% 2.4% 9.0% 7.4% 5.9% 5.4%
Net margin 3.6% 1.8% 1.0% 2.6% 3.5% 3.0% 3.0% 3.3% 3.3% 1.0% −3.2% −2.5% −3.6% 0.3% 9.2% 4.7% 3.4% 3.0%
Free-cash-flow margin 0.3% −4.0% 5.3% 1.2% 5.4% −0.2% 4.0% 6.5% −0.1% −1.2% 1.1% −1.0% −5.8% −3.6% 7.5% 5.2% 5.2% 3.9%
Cash flow
Cash from operations 5 1 7 4 8 2 7 12 3 2 4 1 −8 −4 20 15 19 15
Capital spending 4 5 1 2 2 3 2 3 3 4 2 2 2 4 4 2 4 4
Free cash flow 0 −4 5 1 6 −0 5 9 −0 −2 2 −1 −10 −8 15 13 15 11
Stock-based pay — — 0 0 0 0 0 0 0 0 0 1 1 1 1 1 2 4
Free cash flow after stock pay — — 5 1 6 −0 5 9 −1 −2 1 −2 −11 −9 14 11 13 7
Balance sheet
Cash 2 2 6 6 6 3 5 13 10 11 4 5 4 8 23 15 10 8
Total debt 0 10 10 3 4 4 3 2 2 1 5 — 2 4 3 39 20 19
Net debt (negative = net cash) −2 8 4 −3 −2 1 −2 −10 −7 −9 0 −5 −3 −4 −20 24 10 11
Diluted shares 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m 3m
Returned to shareholders
Dividends 1 1 1 1 1 1 1 2 2 2 1 0 — — — — — —
Buybacks — — — — — — — — — — — — — 0 2 2 0 —
Total returned 1 1 1 1 1 1 1 2 2 2 1 0 — 0 2 2 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · July 31, 2026
What it owns · $176m
Short-term assets $104mLonger-term assets $72m
What it owes, and who funded it · $174m
Short-term liabilities $47mLonger-term liabilities $51mShareholders' equity $75m
  • Short-term assets cover short-term liabilities $104m of assets due within a year against $47m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $104m short-term assets against $51m of longer-dated liabilities.
  • More cash than debt $8m of cash against $19m of debt.
  • Debt below 40% of shareholders' equity Debt is 25% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $15m of operating cash flow against $19m of debt.
  • Operating profit covers interest at least five times over Operating income of $15m against $3m of interest.

From Kewaunee Scientific Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$3.6M
Diluted share count
−0.2%
year over year
Days sales outstanding
77 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in industrial machinery & supplies & components
Last 12 months unless stated KEQU GHM PPIH TWIN HURC AP Median
Revenue, last 12 months $277m $261m $226m $381m $183m $428m $1.4bn
Revenue growth, last 12 months 5.3% 21.2% 24.8% 11.9% −1.9% 3.3% 8.3%
Revenue growth, 3-year average 8.1% 15.7% 17.6% 11.2% −6.6% 1.8% 4.0%
Revenue growth, latest quarter −6.7% 28.6% 24.4% 18.3% 3.2% −9.0% 9.1%
Gross margin 28.6% 23.3% 31.1% 26.9% 21.4% 17.3% 35.2%
Operating margin 5.4% 5.4% 12.1% 3.6% −2.8% −11.1% 13.1%
Operating margin, 3-year average 7.2% 5.6% 12.3% 3.1% −3.0% −5.8% 13.7%
Net margin 3.0% 4.5% 6.9% 7.1% −3.6% −13.8% 8.9%
Cash from operations / revenue 5.3% 2.1% 10.5% 6.0% 4.9% 2.5% 11.9%
Free-cash-flow margin 3.9% −2.3% 6.0% 2.4% 4.6% −0.9% 8.8%
Free-cash-flow margin, 3-year average 4.9% 0.8% 4.7% 4.5% 3.7% −1.3% 9.8%
Stock pay / revenue 1.3% 0.9% 0.6% — 0.9% 0.3% 0.8%
Change in share count −0.2% 2.0% 2.5% 3.1% −0.3% 2.2% −0.0%

Median of all 76 companies we cover in industrial machinery & supplies & components. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

76 industrial machinery & supplies & components companies
Measure Company Peer median Rank
Revenue growth Growth 5.3% 8.3% 56 of 75
Change in growth rate Growth -11.9pp +1.2pp 69 of 75
Gross margin Profitability 28.6% 35.4% 51 of 70
Operating margin Profitability 5.4% 13.0% 51 of 75
Net margin Profitability 3.0% 8.9% 52 of 76
Free-cash-flow margin Cash generation 3.9% 9.1% 51 of 76
Stock pay as % of revenue Cash generation 1.3% 0.8% 51 of 70
Long-term debt as % of assets Balance sheet 7.9% 23.4% 9 of 59
Change in share count Balance sheet -0.2% -0.0% 34 of 73
Days sales outstanding Balance sheet 77 days 63 days 50 of 65

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to April 30, 2026
Segments
Line of business Revenue Share YoY
Laboratory Products Group LPG $215M 76.2% ▲ 19.8%
International Operations $67.1M 23.8% ▲ 9.9%

From Kewaunee Scientific Corp's 10-K filed June 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$42.6M
Institutions reporting
32
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
1 / 1

Top buyers and sellers, Q2 2026: 11 institutions bought and 8 sold ; the biggest buyer was Minerva Advisors LLC (+13K shares) and the biggest seller Northern Trust Corp (−7,853). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Northern Trust Corp $8.5M 238K 19.8% ▼ 3.2%
Dimensional Fund Advisors LP $6.2M 175K 14.6% ▼ 1.3%
Minerva Advisors LLC $5.3M 149K 12.4% ▲ 9.3%
Vanguard Capital Management LLC $3.9M 110K 9.2% ▼ 2.2%
Punch & Associates Investment Management, Inc. $3.7M 106K 8.8% ▲ 4.8%
Renaissance Technologies LLC $3.4M 95K 7.9% ▼ 3.2%
De Lisle Partners LLP $1.9M 53K 4.5% 0.0%
Royce & Associates LP $1.8M 50K 4.1% ▲ 3.5%
American Century Companies Inc $1.8M 50K 4.1% 0.0%
Geode Capital Management, LLC $885,830 25K 2.1% ▲ 1.8%
Mink Brook Asset Management LLC $761,797 21K 1.8% 0.0%
Northeast Investment Management $710,400 20K 1.7% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kewaunee Scientific Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $293,168 7 trades by 2 insiders · 0% under pre-set plans
Net ▼ $293,168 net selling
Insider Date Trade Shares Price Value
Hull Thomas David Iii President, CEO January 7, 2026 Sell 2,177 $37.50 $81,638
Gardner Donald T. Iii Chief Financial Officer January 6, 2026 Sell 2,000 $37.57 $75,140
Hull Thomas David Iii President, CEO December 31, 2025 Sell 629 $37.66 $23,688
Hull Thomas David Iii President, CEO December 30, 2025 Sell 29 $38.00 $1,102
Hull Thomas David Iii President, CEO December 29, 2025 Sell 884 $38.01 $33,601
Hull Thomas David Iii President, CEO December 22, 2025 Sell 1,000 $39.00 $39,000
Hull Thomas David Iii President, CEO December 17, 2025 Sell 1,000 $39.00 $39,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 9, 2026 estimated from the company's past filing pattern, not announced

  • September 9, 2026
  • June 23, 2026
  • March 11, 2026
  • December 10, 2025
  • September 10, 2025
  • June 26, 2025

Recent SEC filings

Data status

When each part of this page on Kewaunee Scientific Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kewaunee Scientific Corp in brief

What does Kewaunee Scientific Corp do?
Kewaunee Scientific Corp is a US-listed company in the industrial machinery & supplies & components industry. Its financial year ends in April.
What is Kewaunee Scientific Corp's stock ticker?
Kewaunee Scientific Corp trades under the ticker KEQU on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Kewaunee Scientific Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Kewaunee Scientific Corp reported revenue of $277M, 5.3% higher than a year earlier, according to its SEC filings.
What is Kewaunee Scientific Corp's free cash flow?
Kewaunee Scientific Corp's free-cash-flow margin is 3.9% of revenue over the trailing twelve months, ranking 51 of the 76 industrial machinery & supplies & components companies we cover.
Who are Kewaunee Scientific Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Northern Trust Corp, Dimensional Fund Advisors LP and Minerva Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Kewaunee Scientific Corp's market cap?
On November 2, 2026, Kewaunee Scientific Corp's market capitalisation was about $99.3M, with a price-to-earnings ratio of 12.1 and net debt of $10.6M. Market figures come from third-party market data and may be delayed.
How much debt does Kewaunee Scientific Corp have?
Kewaunee Scientific Corp's debt-to-equity ratio is 25.1%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Kewaunee Scientific Corp's competitors?
In our Industrial Machinery & Supplies & Components peer group, the companies closest to Kewaunee Scientific Corp are Graham Corp, Perma-pipe International Holdings, Inc., Twin Disc Inc, Hurco Companies Inc and Ampco Pittsburgh Corp. The side-by-side comparison below sets their revenue, margins and growth against Kewaunee Scientific Corp's.
Are insiders buying or selling Kewaunee Scientific Corp stock?
Over the last 12 months, Kewaunee Scientific Corp's directors and officers reported 0 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is Kewaunee Scientific Corp's next earnings date?
Around December 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kewaunee Scientific Corp announces its own schedule.